TN2009000408A1 - Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor - Google Patents
Combination anticoagulant therapy with a compound that acts as a factor xa inhibitorInfo
- Publication number
- TN2009000408A1 TN2009000408A1 TNP2009000408A TN2009000408A TN2009000408A1 TN 2009000408 A1 TN2009000408 A1 TN 2009000408A1 TN P2009000408 A TNP2009000408 A TN P2009000408A TN 2009000408 A TN2009000408 A TN 2009000408A TN 2009000408 A1 TN2009000408 A1 TN 2009000408A1
- Authority
- TN
- Tunisia
- Prior art keywords
- inhibitor
- acts
- factor
- compound
- anticoagulant therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91185207P | 2007-04-13 | 2007-04-13 | |
PCT/US2008/004760 WO2008127682A2 (fr) | 2007-04-13 | 2008-04-11 | Combinaison d'une thérapie anticoagulante à un composé agissant en tant qu'inhibiteur de facteur xa |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2009000408A1 true TN2009000408A1 (en) | 2011-03-31 |
Family
ID=39638994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2009000408A TN2009000408A1 (en) | 2007-04-13 | 2009-10-09 | Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor |
Country Status (17)
Country | Link |
---|---|
US (3) | US20080254036A1 (fr) |
EP (2) | EP2155195B1 (fr) |
JP (2) | JP5469595B2 (fr) |
KR (1) | KR101473207B1 (fr) |
CN (2) | CN101743001B (fr) |
AU (1) | AU2008239659B2 (fr) |
BR (1) | BRPI0809655B8 (fr) |
CA (1) | CA2683793C (fr) |
DO (1) | DOP2009000244A (fr) |
EA (1) | EA020531B1 (fr) |
GT (1) | GT200900260A (fr) |
HK (1) | HK1141230A1 (fr) |
IL (1) | IL201433A (fr) |
MX (1) | MX2009010953A (fr) |
NZ (1) | NZ580162A (fr) |
TN (1) | TN2009000408A1 (fr) |
WO (1) | WO2008127682A2 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1259485B1 (fr) | 2000-02-29 | 2005-11-30 | Millennium Pharmaceuticals, Inc. | Benzamides et inhibiteurs associes du facteur xa |
US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
CA2565437A1 (fr) * | 2004-06-18 | 2006-01-05 | Millennium Pharmaceuticals, Inc. | Inhibiteurs du facteurs xa |
WO2007112367A2 (fr) * | 2006-03-27 | 2007-10-04 | Portola Pharmaceuticals, Inc. | Modulateurs des canaux potassiques et activité procoagulante plaquettaire |
JP5227311B2 (ja) | 2006-05-05 | 2013-07-03 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | 第Xa因子阻害剤 |
EP2077995B1 (fr) * | 2006-11-02 | 2012-02-08 | Millennium Pharmaceuticals, Inc. | Procédés de synthèse de sels pharmaceutiques d'un inhibiteur du facteur xa |
JP2010515691A (ja) * | 2007-01-05 | 2010-05-13 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 第Xa因子阻害剤 |
KR101509829B1 (ko) * | 2007-05-02 | 2015-04-06 | 포톨라 파마슈티컬스, 인코포레이티드 | 혈소판 adp 수용체 억제제로 작용하는 화합물을 이용한 병용요법 |
US9427448B2 (en) | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
SI2498731T1 (sl) | 2009-11-11 | 2020-05-29 | Chiesi Farmaceutici S.P.A. | Postopki zdravljenja ali preprečevanja tromboze stenta |
US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
WO2011084652A2 (fr) | 2009-12-17 | 2011-07-14 | Millennium Pharmaceuticals, Inc. | Sels et formes cristallines d'inhibiteur de facteur xa |
US8742120B2 (en) * | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
AR079491A1 (es) | 2009-12-17 | 2012-02-01 | Millennium Pharm Inc | Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura. |
ES2548845T3 (es) * | 2009-12-23 | 2015-10-21 | Ratiopharm Gmbh | Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico |
US20120052058A1 (en) * | 2010-08-30 | 2012-03-01 | Emory University | Methods of managing the blood coagulation and pharmaceutical compositions related thereto |
TW201240664A (en) * | 2010-09-01 | 2012-10-16 | Portola Pharm Inc | Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor |
TW201221128A (en) | 2010-09-01 | 2012-06-01 | Portola Pharm Inc | Crystalline forms of a factor Xa inhibitor |
US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
US20140346397A1 (en) | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
US10603316B2 (en) | 2013-08-21 | 2020-03-31 | Morehouse School Of Medicine | Composition and methods for preventing or reducing the incidence of transient ischemic attacks |
WO2015038968A1 (fr) * | 2013-09-13 | 2015-03-19 | The General Hospital Corporation | Sondes de liaison à la fibrine activables |
WO2017091757A1 (fr) | 2015-11-24 | 2017-06-01 | Portola Pharmaceuticals, Inc. | Bétrixaban enrichi en isotopes |
US20190300483A1 (en) * | 2016-06-02 | 2019-10-03 | Dr. Reddy's Laboratories Limited | POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT |
CA3060345A1 (fr) | 2017-06-23 | 2018-12-27 | Chiesi Farmaceutici S.P.A. | Procede de prevention de thrombose de shunt de l'artere systemique-pulmonaire |
EP3846626A4 (fr) * | 2018-08-28 | 2022-08-17 | Morehouse School of Medicine | Composition et méthodes pour la prévention ou la réduction de l'incidence d'accidents ischémiques transitoires |
EP4070658A1 (fr) * | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Utilisation de composés anticoagulants comme rodenticides |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995029189A1 (fr) | 1994-04-26 | 1995-11-02 | Selectide Corporation | INHIBITEURS DU FACTEUR Xa |
ES2216625T3 (es) * | 1998-11-27 | 2004-10-16 | ABBOTT GMBH & CO. KG | Bencimidazoles substituidos y su empleo como inhibidores de parp. |
US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
CN1390206A (zh) * | 1999-09-17 | 2003-01-08 | 千嬉药品公司 | 因子Xa的抑制剂 |
BR0014076A (pt) * | 1999-09-17 | 2002-10-15 | Millennium Pharm Inc | Benzamidas e inibidores correlatos do fator xa |
US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
EP1259485B1 (fr) * | 2000-02-29 | 2005-11-30 | Millennium Pharmaceuticals, Inc. | Benzamides et inhibiteurs associes du facteur xa |
GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
US20040192753A1 (en) | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
US6686193B2 (en) * | 2000-07-10 | 2004-02-03 | Vertex Pharmaceuticals, Inc. | High throughput method and system for screening candidate compounds for activity against target ion channels |
US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
HRP20000765A2 (en) | 2000-11-10 | 2002-06-30 | Pliva D D | Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release |
DE10065475A1 (de) * | 2000-12-28 | 2002-07-18 | Switch Biotech Ag | Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion |
AU2002258394A1 (en) * | 2001-02-07 | 2002-09-12 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam3 |
US7312235B2 (en) * | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
US20030129193A1 (en) * | 2001-09-27 | 2003-07-10 | Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. | Combined methods for tumor vasculature coaguligand treatment |
US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
FR2838057B1 (fr) * | 2002-04-05 | 2005-07-08 | Servier Lab | Nouvelle association d'un antithrombotique et d'aspirine |
US20040067995A1 (en) * | 2002-10-02 | 2004-04-08 | Wong Pancras C. | Novel combination of a factor Xa inhibitor and clopidogrel |
WO2005025511A2 (fr) * | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Administration assistee par les canaux potassiques d'agents a travers la barriere hemato-encephalique |
FR2860436B1 (fr) * | 2003-10-03 | 2006-01-20 | Servier Lab | Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire |
EP1678161B1 (fr) * | 2003-10-09 | 2009-12-30 | Millennium Pharmaceuticals, Inc. | Utilisation de benzamides a substitution thioether en tant qu'inhibiteurs du facteur xa |
DE102004016845A1 (de) * | 2004-04-07 | 2005-10-27 | Bayer Healthcare Ag | Phenylthioessigsäure-Derivate und ihre Verwendung |
US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
CA2565437A1 (fr) * | 2004-06-18 | 2006-01-05 | Millennium Pharmaceuticals, Inc. | Inhibiteurs du facteurs xa |
DE102004046623A1 (de) * | 2004-09-25 | 2006-03-30 | Bayer Healthcare Ag | Neue Pyrimidin-Derivate und ihre Verwendung |
DE102005027150A1 (de) * | 2005-03-12 | 2006-09-28 | Bayer Healthcare Ag | Pyrimidincarbonsäure-Derivate und ihre Verwendung |
US20090226412A1 (en) * | 2005-06-24 | 2009-09-10 | Ono Pharmaceutical Co., Ltd., | Agent for reduction of bleeding in cerebrovascular disorder |
ATE549317T1 (de) * | 2005-11-08 | 2012-03-15 | Millennium Pharm Inc | Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer |
WO2007112367A2 (fr) | 2006-03-27 | 2007-10-04 | Portola Pharmaceuticals, Inc. | Modulateurs des canaux potassiques et activité procoagulante plaquettaire |
JP5227311B2 (ja) | 2006-05-05 | 2013-07-03 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | 第Xa因子阻害剤 |
EP2077995B1 (fr) * | 2006-11-02 | 2012-02-08 | Millennium Pharmaceuticals, Inc. | Procédés de synthèse de sels pharmaceutiques d'un inhibiteur du facteur xa |
PT2101760E (pt) * | 2006-12-08 | 2013-05-07 | Millennium Pharm Inc | Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa |
JP2010515691A (ja) * | 2007-01-05 | 2010-05-13 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 第Xa因子阻害剤 |
KR101509829B1 (ko) * | 2007-05-02 | 2015-04-06 | 포톨라 파마슈티컬스, 인코포레이티드 | 혈소판 adp 수용체 억제제로 작용하는 화합물을 이용한 병용요법 |
-
2008
- 2008-04-11 US US12/101,644 patent/US20080254036A1/en not_active Abandoned
- 2008-04-11 CN CN200880019506XA patent/CN101743001B/zh not_active Expired - Fee Related
- 2008-04-11 JP JP2010503078A patent/JP5469595B2/ja not_active Expired - Fee Related
- 2008-04-11 NZ NZ580162A patent/NZ580162A/xx not_active IP Right Cessation
- 2008-04-11 CN CN2012105706089A patent/CN103071154A/zh active Pending
- 2008-04-11 KR KR1020097023491A patent/KR101473207B1/ko active IP Right Grant
- 2008-04-11 EP EP08742820.7A patent/EP2155195B1/fr active Active
- 2008-04-11 MX MX2009010953A patent/MX2009010953A/es active IP Right Grant
- 2008-04-11 CA CA2683793A patent/CA2683793C/fr not_active Expired - Fee Related
- 2008-04-11 EP EP12196044.7A patent/EP2591783A1/fr not_active Withdrawn
- 2008-04-11 AU AU2008239659A patent/AU2008239659B2/en not_active Ceased
- 2008-04-11 WO PCT/US2008/004760 patent/WO2008127682A2/fr active Application Filing
- 2008-04-11 BR BRPI0809655A patent/BRPI0809655B8/pt not_active IP Right Cessation
- 2008-04-11 EA EA200970946A patent/EA020531B1/ru not_active IP Right Cessation
-
2009
- 2009-10-07 GT GT200900260A patent/GT200900260A/es unknown
- 2009-10-09 TN TNP2009000408A patent/TN2009000408A1/fr unknown
- 2009-10-11 IL IL201433A patent/IL201433A/en active IP Right Grant
- 2009-10-12 DO DO2009000244A patent/DOP2009000244A/es unknown
-
2010
- 2010-08-10 HK HK10107664.8A patent/HK1141230A1/xx not_active IP Right Cessation
-
2011
- 2011-08-19 US US13/213,912 patent/US8455440B2/en not_active Expired - Fee Related
-
2013
- 2013-05-08 US US13/889,982 patent/US20130315897A1/en not_active Abandoned
- 2013-06-18 JP JP2013127495A patent/JP2013177459A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2009000408A1 (en) | Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor | |
EA200901442A1 (ru) | Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах | |
MX2010002353A (es) | Amidas heterociclicas utiles para tratamiento de cancer y psoriais. | |
CY2016015I1 (el) | Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων | |
MX343740B (es) | Derivados de bencilamina como inhibidores de calicreina plasmatica. | |
MX2009006706A (es) | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
EA024702B8 (ru) | Новые иммуномодуляторные и противовоспалительные соединения | |
EA201270215A1 (ru) | Apaf-1 ингибиторные соединения | |
JO2870B1 (en) | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes | |
PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
EA201000750A1 (ru) | Производные 4-бензиламино-1-карбоксиацилпиперидина, как ингибиторы бпхэ (белка-переносчика холестериловогоэфира), применимые для лечения заболеваний, таких как гиперлипидемия или артериосклероз | |
GEP20146197B (en) | New compounds | |
MX2008012490A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
MY146662A (en) | Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | |
ATE456571T1 (de) | Proteasom-hemmer und verwendungsverfahren dafür | |
EA200802050A1 (ru) | Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов | |
NZ601483A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
EA201001683A1 (ru) | Производные фенил- или пиридинилзамещенных индазолов | |
MX2009007104A (es) | Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina. | |
EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
TN2011000234A1 (en) | Heterocyclically substituted aryl compounds as hif inhibitors | |
IN2012DN00721A (fr) | ||
EA201000098A1 (ru) | Производные хиназолинамида | |
ATE524450T1 (de) | 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren | |
MY186456A (en) | Quinazoline carboxamide azetidines |